Lixisenatide has neutral effect on heart failure and other cardiovascular outcomes.
ADA 75th Scientific Sessions 2015 Complete Coverage
Competitive bidding reduces access to diabetes supplies and increases mortality for Medicare patients.
Induced pluripotent stem cells offer a new way to study insulin resistance and other metabolic disorders in humans.
During the past 50 years, diabetes research and management has come a long way, although there is still work to be done.
Activity in certain brain regions of teenagers with type 1 diabetes was increased or decreased with hyperglycemia and hypoglycemia.
PE0139, a super long-acting basal insulin, and PB1023, a weekly GLP-1 receptor agonist, may lead to novel approach to treating diabetes.
Unsupervised closed loop insulin delivery is safe and feasible in the home setting in teens with type 1 diabetes.
Continuous glucose monitoring can reduce costs associated with diabetes and improve quality of life.
Adding lixisenatide to insulin glargine is comparable to other insulin regimens for controlling HbA1c in type 2 diabetes.
Adding liraglutide to insulin in a closed loop system may reduce postprandial hyperglycemia as well as insulin requirements, compared with insulin monotherapy.
Researchers will look at effects in people with longstanding disease,
Children may have a higher risk for fat accumulation and insulin resistance if their mothers were obese.
Food insecurity has an impact on glycemic control and vegetable consumption in Latino patients with diabetes.
Gut-based medications like GLP-1 agonists may induce weight loss by reducing cravings and increasing satiety.
GLP-1 receptor agonist may be able to reduce glycemic variability rather than a prandial insulin.
Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.
ITCA 650, which continuously delivers exenatide subcutaneously, yielded improvements in HbA1c and body weight in patients with type 2 diabetes.
Compared with insulin glargine, once-weekly dulaglutide led to superior reductions in HbA1c in patients with type 2 diabetes.
People with type 1 diabetes treated with basal insulin peglispro vs. insulin glargine had significantly lower HbA1c levels at 26 and 52 weeks.
Achieving greater HbA1c reductions with fixed-ratio combination insulin glargine/lixisenatide did not increase rates of hypoglycemia.
Patients with type 2 diabetes and cardiovascular disease may benefit from long-term treatment with dapagliflozin.
Sign Up for Free e-Newsletters
Check out what's trending
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation